# Louisiana Man Achieves Functional Cure of Sickle Cell Disease
Daniel Cressy became the first person in Louisiana to achieve functional remission of sickle cell disease through a groundbreaking stem cell transplant procedure. The 34-year-old patient received treatment that modifies his own blood cells to produce healthy hemoglobin, effectively stopping the disease from progressing.
Sickle cell disease affects approximately 100,000 Americans, predominantly people of African descent. The inherited blood disorder causes red blood cells to become rigid and crescent-shaped, blocking blood vessels and causing severe pain, organ damage, and shortened lifespans. Patients often experience painful episodes multiple times yearly and require frequent hospitalizations.
Cressy's treatment involved extracting his own stem cells, genetically modifying them in a laboratory to produce normal hemoglobin, then reinfusing the edited cells back into his body. This approach avoids the risks associated with traditional bone marrow transplants, which require finding a matched donor and carry rejection risks. The procedure represents a significant advance in gene therapy for blood disorders.
The treatment follows FDA approvals of two gene-editing therapies for sickle cell disease in late 2023. Exagamglogene autotemcel (from Vertex Pharmaceuticals and CRISPR Therapeutics) and lovotibeglogene autotemcel (from Bluebird Bio) both modify patients' own cells to restore healthy hemoglobin production. Clinical trials showed patients receiving these treatments experienced dramatic reductions in vaso-occlusive crises, the severe pain episodes that characterize the disease.
For Cressy, the functional cure means freedom from the constant pain and limitations that defined his life. He no longer experiences the debilitating crises that previously made daily activities unpredictable.
Access remains a